AI-Powered Growth & Sales Acceleration Program
Genostim Performance Labs · Prepared by the Pet Jet LLC Advisory Consortium
Confidential · April 2026Client Proposal
~$10B
Combined TAM Across 3 Revenue Streams
$83M
Year 5 Revenue Target — Conservative Base Case
3
Separate Revenue Streams — Zero Crossover Between Them
818×
Digital Traffic Gap vs. BodyBio Benchmark
Advisory Consortium
Four Firms. One Aligned Mission.
Pet Jet LLC
Lead consortium entity; DTC growth, digital infrastructure, and consumer brand strategy
Scale Foundry
B2B commercial architecture, manufacturing operations, and supply chain strategy
TIN (The Information Network)
Market intelligence, competitive analysis, and technology ecosystem integration
Velocity Partners International
International market development, strategic partnership identification, and investor relations
Proposal at a Glance
~$10B
Combined TAM Across 3 Revenue Streams
$83M
Year 5 Revenue Target
Conservative Base Case
3
Separate Revenue Streams
Human · Pet · Collagen B2B
818×
Digital Traffic Gap vs. BodyBio Benchmark
$2.1M
Year 1 Combined Revenue Target
15–20%
Advisory Equity Stake
3-yr vest, zero cash fees
Executive Summary
A Three-Stream Commercial Platform
The Opportunity
Genostim Performance Labs stands at a rare strategic inflection point. Built on 20+ years of proprietary peptide research by Lauriston Crockett III, the company has developed a science-first collagen platform applicable across three entirely separate, multi-billion-dollar markets — each with its own regulatory pathway, distribution infrastructure, and end customer.
Key Highlights
  • Three revenue streams totaling ~$10B combined TAM — structurally independent, zero crossover
  • Y5 conservative target: $83M combined ($22.5M human + $20M pet + $40.5M collagen B2B)
  • Proprietary ISOTIDE™ pinocytosis delivery mechanism — 20+ years R&D, 28 bioactive growth factors
  • 818× digital traffic gap vs. BodyBio — infrastructure problem, not a product problem
  • Advisory-for-equity structure: 15–20% equity, 3-yr vest, zero cash fees, co-investment support
  • Regulatory strategy required before scaling: GHK-Cu warning letter environment demands counsel now
The Engagement Model
Market Opportunity
Three Revenue Streams — One Platform
Stream 1 — Human Peptides
Genostim® Brand
US collagen peptide market: $2.5B in 2025, 12.9% CAGR → $4.9B by 2030. Governed by DSHEA. Channels: DTC e-commerce, Amazon, HCP, specialty retail. Y5 target: $22.5M.
Stream 2 — Pet Peptides
TGFL® / The Gift For Life® Brand
US pet supplement market: $4.76B in 2025, 10% CAGR. Governed by AAFCO. Channels: Vet clinics, DTC/Chewy, PetSmart, Petco. Y5 target: $20.0M.
Stream 3 — Collagen B2B Ingredient Supply
US collagen ingredient market: $2.7B in 2025, ~8% CAGR. Governed by GRAS. Channels: F&B manufacturers, nutraceutical brands, cosmetics formulators. Y5 target: $40.5M.
Stream 1 — Human Peptides
Stream 1 — Human Peptides — Genostim® Brand
Market Context
The US collagen peptide supplement market is valued at approximately $2.5 billion in 2025, expanding at a 12.9% CAGR with a projected value of $4.9 billion by 2030. The five dominant players (Vital Proteins/Nestle, Ancient Nutrition, NeoCell, Sports Research, and Momentous) collectively control approximately 65% of market share — leaving meaningful white space for a science-differentiated challenger brand.
Genostim's differentiation: The 3-Layer Regeneration System — BUILD (Collagen Peptides) + ABSORB (Probiotics) + ACTIVATE (ISOTIDE™ Peptides) — combined with 28 bioactive growth factors, 18 amino acids, and a pinocytosis delivery mechanism.
Positioning: "This isn't just collagen. This is collagen that knows what to do."
Revenue Penetration Model
Channel Strategy:
  • DTC e-commerce (genostim.com) — primary revenue and margin engine
  • Amazon — secondary channel for discoverability and review volume
  • Health professional (HCP) channel — physicians, functional medicine practitioners, registered dietitians
  • Specialty retail — Sprouts, Whole Foods, The Vitamin Shoppe
Stream 2 — Pet Peptides
Stream 2 — Pet Peptides — The Gift For Life® Brand
Market Context
The US pet supplement market reached approximately $4.76 billion in 2025, expanding at 10% annually, driven by pet humanization. Primary competitors — Zesty Paws, Nutramax (Cosequin), VetriScience, and PetHonesty — compete primarily on price and retail shelf placement. None has a proprietary peptide delivery mechanism comparable to the ISOTIDE™ platform.
Key Differentiators — Pet vs. Human
  • Entirely separate brand identity: TGFL® / The Gift For Life® — no connection to Genostim® human brand
  • Separate regulatory team and compliance infrastructure (AAFCO, not DSHEA)
  • Separate sales team: field-based vet relationship managers
  • Palatability is mission-critical: chicken, beef, and bacon flavor profiles require palatability testing
  • Autoship economics on Chewy create predictable recurring revenue
Revenue Penetration Model
Regulatory Framework — AAFCO / NASC
Pet supplements are governed by AAFCO — not FDA dietary supplement law. Products must be registered state-by-state (3–9 months per state). NASC Quality Seal is effectively required for serious vet channel distribution. NASC certification is a Year 1 priority with an estimated 6–9 month implementation timeline.
Stream 3 — Collagen B2B
Stream 3 — Collagen B2B Ingredient Supply — New Market Entry
Market Context
The US collagen ingredient market — serving food and beverage manufacturers, cosmetics formulators, and pharmaceutical companies — is valued at approximately $2.7 billion in 2025. The F&B segment accounts for 57% of this market. The global market is dominated by five suppliers: Rousselot (PB Leiner parent), Gelita AG, Nitta Gelatin, and Chinese manufacturers.
Genostim's competitive differentiation rests on three pillars: Made in USA / Texas sourcing, grass-fed and traceable supply chain, and a bioactive profile (28 growth factors, proprietary peptide processing) that generic commodity hydrolysate cannot replicate.
Business Model — B2B Ingredient Supply
  • Target customers: food & beverage manufacturers (protein bars, RTDs, functional foods), nutraceutical brands, cosmetics formulators
  • Pricing model: per-kilogram ingredient pricing + volume tier contracts; minimum order quantities; annual supply agreements
  • Sales motion: direct B2B enterprise sales, trade show presence (SupplySide West, IFT Food Expo, Cosmoprof), broker/distributor network
  • Regulatory: GRAS pathway — collagen is a well-established GRAS ingredient; voluntary FDA GRAS notification recommended
Revenue Ramp — Starting from Zero
B2B sales cycles of 6–18 months from first contact to purchase order. Capital investment required for SQF, FSMA compliance, and COAs.
TAM · SAM · SOM — Three Streams
Revenue Scenarios
Revenue Scenarios — All Three Streams
Financial Model
36-Month Cash Flow Projection
Model reaches EBITDA break-even in Year 3. Year 1 deficit funded through consortium co-investment syndication of $500K–$2M.
Financial Model — Key Assumptions
Blended COGS ~40%
Improving to 35% at scale through manufacturing efficiency across all three streams.
Sales & Marketing 25%
DTC-heavy in Years 1–2, normalizing to 20% by Year 3 as organic traffic and brand equity build.
G&A / Operations 15%
Scales proportionally with revenue; shared infrastructure across streams where possible.
R&D / Clinical 10%
Held constant to fund the human clinical trial program and formulation development for pet and B2B streams.
Co-Investment Funding
Year 1 deficit of $0.8M funded through consortium co-investment syndication of $500K–$2M. No external equity raise assumed in base case.
Break-Even Y3
Model reaches EBITDA break-even in Year 3 and positive cumulative cash position by mid-Year 3.
Science Platform
Science Platform — ISOTIDE™ / Hexatide™ Complex
01
LAYER 1 — BUILD (Collagen Peptides)
Grass-fed, US-sourced collagen hydrolysate providing the structural amino acid substrate — 18 amino acids including high concentrations of glycine, proline, and hydroxyproline — for connective tissue synthesis.
02
LAYER 2 — ABSORB (Probiotics)
A probiotic complex designed to optimize the gut environment for collagen peptide absorption. Improves bioavailability of the peptide fraction reaching systemic circulation.
03
LAYER 3 — ACTIVATE (ISOTIDE™ Peptides)
The proprietary differentiated element. ISOTIDE™ peptides function through a pinocytosis delivery mechanism — delivering 28 identified bioactive growth factors directly to target tissues.
Clean. Clinical. Powerful.
Regulatory Strategy
Regulatory Environment — Three Separate Compliance Stacks
Stream 1 — Human Supplements: DSHEA Framework
DSHEA governs all human dietary supplement marketing. Collagen is a pre-existing ingredient — no NDI notification required. Structure/function claims permitted but require: (1) claim substantiation file, (2) FDA notification within 30 days, (3) mandatory disclaimer on all materials.
Stream 2 — Pet Supplements: AAFCO / NASC Framework
Pet supplements are governed by AAFCO — not FDA dietary supplement law. Every state requires a separate product registration (30 days to 9 months per state). A 50-state registration program requires 18–24 months to complete fully. NASC Quality Seal is effectively required for serious vet channel distribution. NASC certification is a Year 1 priority (6–9 month timeline).
Stream 3 — Collagen B2B Ingredient: GRAS Pathway
Collagen hydrolysate is eligible for GRAS status. Voluntary FDA GRAS notification recommended for premium B2B positioning. Additional requirements: SQF certification (manufacturing), FSMA compliance (ingredient suppliers), Kosher/Halal certification, NSF certification for pharmaceutical-grade customers. Prioritize SQF and FSMA in Year 1 as gating criteria for first anchor contracts.
Clinical Strategy
Human Clinical Trials Pathway
A proprietary clinical study is the most durable competitive moat available to a science-first supplement brand. It enables structure/function claim substantiation at a standard no competitor can quickly replicate, unlocks HCP endorsement at scale, supports premium pricing, and creates category authority in earned media.
Recommended Endpoints — Full RCT
  • Skin elasticity (Cutometer measurement)
  • Joint comfort (WOMAC or VAS scale)
  • Biomarkers of collagen synthesis (serum C-propeptide of type I procollagen)
  • Self-reported functional outcomes (validated quality-of-life instrument)
  • Secondary: gut health markers (stool consistency, bloating VAS) to validate the probiotic ABSORB layer
All human clinical trials must be registered on ClinicalTrials.gov before the first participant is enrolled. Competitive bidding across 2–3 CROs recommended. Budget should include 15–20% contingency for protocol amendments and participant retention challenges.
Competitive Analysis
Strengths & Weaknesses — All Three Markets
An honest, unvarnished assessment of competitive position across all three revenue streams. Green represents genuine structural advantages. Red represents real risks and gaps the consortium's program is designed to address.
Product Attributes — What Sets Genostim Apart
The Science Advantage
The science underlying Genostim Performance Labs is proprietary, patentable, and commercially differentiated in ways that standard hydrolyzed collagen products are not. Developed over 20+ years by Lauriston Crockett III.
Product Attributes
  • 28 Bioactive Growth Factors: Identified and characterized in the ISOTIDE™ complex; clinical dossier available
  • 18 Amino Acids: Complete amino acid profile including all conditionally essential amino acids relevant to connective tissue
  • Third-Party Tested: Certificate of Analysis available; testing panel includes heavy metals, microbial, potency
  • Clean Label: Grass-Fed, Gluten Free, Non-GMO, No Artificial Ingredients — positioned for clean-label premium retail
  • Made in Texas, Sourced in America: Domestic supply chain is a material differentiator in a market where most collagen is sourced from Brazil or Argentina
Digital Strategy
Closing the 818× Digital Gap
Genostim's organic traffic value is approximately $275/month vs. BodyBio's $224,911/month — an 818× deficit. The Information Network (TIN) brings custom AI tooling trained on Genostim's proprietary science library, Crockett's Peptide Effect series, and competitive keyword data to produce a content engine generating topical authority across peptide, anti-aging, cellular health, and pet wellness categories.
Root Causes
  • Website technical SEO deficits: crawlability, page speed, Core Web Vitals, schema markup
  • Content infrastructure: zero long-form educational content targeting clinical and wellness search queries
  • Domain authority: limited backlink profile from credible health, science, and wellness publications
  • Product page architecture: insufficient content depth for conversion optimization and search ranking
  • Email capture and CRM infrastructure: likely under-built, limiting lifecycle revenue and LTV
The Consortium
Four Specialized Firms. Complete Coverage.
What the Consortium Brings: Growth Strategy · Digital Infrastructure · Regulatory Navigation · Clinical Trial Design · B2B Channel Development · Financial Architecture · Brand Architecture
Advisory for Equity — Structural Terms
Equity Stake
15–20% combined consortium stake, structured as restricted units
Vesting
3-year vest with 1-year cliff
Cash Fees
Zero — pure advisory-for-equity alignment; no retainer, no hourly billing, no project fees
Co-Investment
$500K – $2M syndication support from consortium network
Engagement Scope
All three revenue streams — Human Peptides, Pet Peptides, and Collagen B2B — from Day 1
Review Period
90-day mutual fit / performance review at 90 days post-close
Go-To-Market Roadmap
Five Phases to Category Leadership — All Three Streams
1
Foundation
Q1–Q2 2026 · Brand refresh for Genostim® and TGFL®. DTC infrastructure rebuild. Technical SEO audit and remediation. Regulatory counsel engagement (DSHEA/GHK-Cu). NASC membership application. SQF certification initiation.
2
Digital Authority
Q3–Q4 2026 · 50-topic content pillar/cluster strategy live. 20+ editorial placements in health, wellness, and clinical publications. Amazon A+ content and review velocity program. First B2B anchor contracts signed. Pilot clinical study initiated.
3
Channel Expansion
Year 2 · Chewy listing + PetSmart pilot for TGFL®. HCP channel launch with clinical dossier. 5–8 active B2B accounts. Full RCT underway. Affiliate and influencer programs at scale.
4
National Scale
Year 3 · National specialty retail rollout (Sprouts, Whole Foods, Vitamin Shoppe). 20+ B2B accounts; broker network in 3 regions. Clinical trial publication. $25.5M combined revenue target.
5
Category Leadership
Year 5 · $83M combined revenue. 75,000+ human subscribers. Full multi-channel pet penetration. 1.5% B2B TAM penetration. Pharmaceutical-grade qualification in progress.
Next Steps — 30-Day Action Plan
01
Execute Advisory Equity Agreement
Establish the consortium board advisory structure (Day 1–30)
02
Engage DSHEA Regulatory Counsel
GHK-Cu / growth factor label review — critical priority (Day 1–30)
03
Commission Technical SEO Audit
Full audit of genostim.com (Day 1–14)
04
Initiate NASC Membership Application
For TGFL® pet brand (Day 1–30)
05
Identify & Brief 3 CROs
For Year 1 pilot clinical study (Day 30–60)
06
Begin SQF Certification Process
For B2B ingredient supply (Day 30–90)
07
Establish Separate Brand P&Ls
Operational tracking for all three streams (Day 30)
The Pet Jet LLC Advisory Consortium will begin immediate execution on the highest-priority legal, regulatory, and growth items, while building the operational foundation for the three business streams.
Confidential · April 2026
Ready to Build Something Exceptional
This proposal is prepared on a confidential basis for Genostim Performance Labs. All market data is sourced from publicly available industry research and is believed to be accurate as of April 2026. Revenue projections are forward-looking estimates subject to market conditions, regulatory developments, and execution factors.
For questions or to initiate the engagement, contact the Pet Jet LLC Advisory Consortium through your designated consortium liaison.
$83M
Year 5 Combined Revenue Target
~$10B
Combined TAM
15–20%
Advisory Equity Stake